An international series of four webinars was successfully organised by Biotech consortium India Limited (BCIL) in association with Asia-Pacific Association of Agricultural Research Institutions (APAARI) based on the theme ‘Popularization of tissue culture raised certified quality plants for its widespread adoption among potential countries in Asia Pacific and Africa’ in the months of May to August, 2022.
 

September 08, 2022

Biotech Consortium India Limited (BCIL) launched its stock culture programme through a virtual programme- ‘Significance of indigenous quality stock culture for Agriculture Industry and enhancing Farmers income’ on 20.04.2022. The programme was formally launched by the Director General, Indian Council of Agricultural Research, Govt. Of India, Dr. Trilochan Mohapatra.
 

Read Full Details

 

April 22, 2022

The webinar on Realizing Potential of Commercial Plant Tissue Culture: Challenges and Way Forward was organized by BCIL on September 9, 2021.

September 13, 2021

The e-licensing ceremony was graced by Dr. Renu Swarup, Secretary, DBT  and dignitaries from ICAR, DAHD, BIRAC, BCIL and M/s Hester Biosciences Pvt. Ltd., Ahmedabad.  

Read Full Details

September 22, 2020

Dr. Purnima Sharma, MD BCIL briefing Hon'ble Prime Minister of India and the President of Kenya about BCIL Activities.

Read Full Details

March 27, 2019

BCIL facilitated licensing of White Rust resistant Mustard technology, developed by Delhi University through DBT support to five companies Hytech Seed India Pvt Ltd, Hyderabad, Rasi Seeds (P), Ganga Kaveri Seeds Pvt Ltd., Metahelix Life Sciences Ltd., Tierra Agrotech Ltd. during 7th Foundation day celebrations of BIRAC on March 19th, 2019 in presence of Dr. Renu Swarup, Secretary DBT and Dr. Mohd. Aslam, MD, BIRAC.

 

March 27, 2019

Attention:-Bioinformatics Programs (BINC and BIITP)

1. Bioinformatics National Certification (BINC) has been merged with DBT-Junior Research Fellow (BET Exam)

2. Bioinformatics Industrial Training Program (BIITP) is merged with HRDBiotechnology Industrial Training Programme (BITP).

March 27, 2019

04.01.2019

Notice Sub: Submission of pending UC, SOE and Claim form

March 27, 2019

Erythropoietin (EPO) is used in many clinical settings for anaemic patients. Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO as these diseases may cause anemia. A second-generation erythropoietin analogue, Darbepoetin alpha, was created aiming longer elimination half-life in vivo that translated into less frequent dosing, usually once weekly or once every 2 week.

March 27, 2019

Milk derived primary Mammary Epithelial Cells (pMECs) are potential tools in pursuit of future scientific breakthrough as they represent 90% of in-vivo environment as compared to transformed cells. Lack of commercial availability of pMECs is a problem faced by scientific community.

March 27, 2019